Skip to content
Peptidepedia

SS-31 (Elamipretide) Stacking Guide: Best Combinations & Protocols (2026)

From Peptidepedia, the trusted peptide wiki.

Stacking

SS-31's mitochondria-specific mechanism is genuinely complementary to several other compounds targeting cellular energy systems. Unlike many peptide stacking combinations that lack mechanistic rationale, combinations with mitochondrial support compounds have scientific logic.

SS-31 + NAD+ Precursors (NMN or NR)

Potentially the most synergistic combination. NAD+ is an essential cofactor for electron transport chain function and a substrate for sirtuins (mitochondrial quality control enzymes). SS-31 optimizes the structural efficiency of the electron transport chain; NAD+ precursors increase the availability of the key electron carrier. Together, they address both the structural and substrate limitations of aging mitochondria.

SS-31 + CoQ10 / Ubiquinol

Coenzyme Q10 functions as an electron carrier between Complexes I/II and Complex III in the electron transport chain. SS-31 stabilizes the protein complexes through which CoQ10 shuttles electrons. These mechanisms are genuinely complementary, with CoQ10 addressing electron carrier availability while SS-31 preserves the structural context in which CoQ10 operates.

SS-31 + PQQ (Pyrroloquinoline Quinone)

PQQ promotes mitochondrial biogenesis through activation of PGC-1α signaling. SS-31 also appears to activate PGC-1α. Their combination may produce additive or synergistic biogenesis stimulation, though direct evidence is lacking.

SS-31 + BPC-157

For tissue healing applications, particularly in post-injury recovery or surgical contexts where both mitochondrial function and tissue repair are priorities. BPC-157 supports angiogenesis and structural repair while SS-31 addresses the cellular energy deficits that accompany tissue injury. No formal research examines this combination.

General Stacking Caution: Formal drug interaction studies are absent for all SS-31 combinations. Establishing individual response to SS-31 alone before adding additional compounds allows clearer attribution of effects and identification of tolerability issues.

Frequently Asked Questions

Formal drug interaction studies are lacking. Theoretically, SS-31 may complement other mitochondrial support compounds including NAD+ precursors, CoQ10/Ubiquinol, and PQQ. It has also been combined with BPC-157 for enhanced tissue healing. Starting with SS-31 alone before adding other compounds is advisable to establish individual response and tolerability.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
  2. Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261.
  3. Daubert MA, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017;10(12):e004230.
  4. Butler J, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020;26(5):429-437.
  5. Thompson R, et al. Current and future treatment approaches for Barth syndrome. J Inherit Metab Dis. 2022;45(1):17-28.
  6. Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.
  7. Stealth BioTherapeutics. Elamipretide Development Program.
  8. Sabbah HN, et al. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016;9(2):e002206.
  9. Gibson CM, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296-1303.
←Read the full SS-31 (Elamipretide) guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”